Regulation of Opioid Receptor Trafficking and Morphine Tolerance by Receptor Oligomerization  by He, Li et al.
Cell, Vol. 108, 271–282, January 25, 2002, Copyright 2002 by Cell Press
Regulation of Opioid Receptor Trafficking
and Morphine Tolerance by Receptor Oligomerization
gesia and dependence are mediated by mu opioid recep-
tors (MORs) (Matthes et al., 1996). Following activation by
either alkaloid or peptide agonist, opioid receptors are
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2 Department of Neurology regulated by multiple mechanisms, including a well-
characterized and highly conserved process involvingUniversity of California, San Francisco
Emeryville, California 94608 receptor phosphorylation by G protein coupled receptor
kinase (GRK) and subsequent arrestin recruitment (re-3 Department of Psychiatry and Cellular and
Molecular Pharmacology viewed in Ferguson, 2001). These processes can con-
tribute directly to GPCR desensitization by facilitatingUniversity of California
San Francisco, California 94143 the uncoupling of receptor from G protein. Following
this desensitization, receptors are often endocytosed
into an intracellular compartment, from which they can
be recycled to the membrane, leading to receptor resen-Summary
sitization, or targeted for degradation, leading to recep-
tor downregulation (Lefkowitz et al., 1998). Hence, theseThe utility of morphine for the treatment of chronic
pain is hindered by the development of tolerance to processes can contribute directly to tolerance by de-
creasing the number of functional cell surface receptors.the analgesic effects of the drug. Morphine is unique
among opiates in its ability to activate the mu opioid Consequently, the prevailing view is that opioid receptor
desensitization and endocytosis contribute directly toreceptor (MOR) without promoting its desensitization
and endocytosis. Here we demonstrate that [D-Ala2- physiological tolerance by reducing the number of func-
tional receptors present. However, morphine-activatedMePhe4-Gly5-ol] enkephalin (DAMGO) can facilitate the
ability of morphine to stimulate MOR endocytosis. As a MORs elude GRK phosphorylation and subsequent ar-
restin binding and desensitization (Blake et al., 1997;consequence, rats treated chronically with both drugs
show reduced analgesic tolerance compared to rats Whistler and von Zastrow, 1998; Zhang et al., 1998).
Additionally, morphine fails to promote endocytosis oftreated with morphine alone. These results demon-
strate that endocytosis of the MOR can reduce the the wild-type MOR in cultured cells (Arden et al., 1995;
Keith et al., 1996) and native neurons (Keith et al., 1998;development of tolerance, and hence suggest an ap-
proach for the development of opiate analogs with Sternini et al., 1996), whereas endogenous peptide li-
gands, such as endorphins, and several opiate drugs,enhanced efficacy for the treatment of chronic pain.
such as methadone, readily drive receptor endocytosis
(Trapaidze et al., 2000). Furthermore, numerous studiesIntroduction
have demonstrated no substantial downregulation in the
number of MORs, even in profoundly tolerant animalsOpioid receptors belong to the large superfamily of G
protein-coupled receptors (GPCRs). As a class, GPCRs (for example, De Vries et al., 1993; Simantov et al., 1984;
reviewed in Williams et al., 2001). Hence, it is unlikelyare of fundamental physiological importance because
they mediate the physiological actions of the majority that tolerance to morphine is mediated solely by desen-
sitization and downregulation of the receptor.of known neurotransmitters and hormones. Opioid re-
ceptors are particularly intriguing members of this re- We propose a different hypothesis for the cell biologi-
cal mechanisms underlying the development of toler-ceptor family because they are activated both by endog-
enously produced opioid peptides and by exogenously ance to opiate drugs that is fully consistent with the
available data and suggests an approach to the pharma-administered opiate drugs (Hughes and Kosterlitz,
1983), which are the most effective analgesics known, cotherapy of chronic pain. We propose that the regula-
tion of opioid receptors by endocytosis serves a protec-as well as highly addictive drugs of abuse. While opiates
such as morphine remain the analgesic of choice in tive role in reducing the development of tolerance to
many cases, a major limitation to their long-term use is opiate drugs specifically because this mechanism regu-
the development of tolerance, a profound decrease in lates signaling in a rapid and reversible way. The ability
analgesic effect observed in most patients during pro- of an agonist to promote endocytosis of the MOR is
longed administration of opiate drug. In addition, long- not linearly related with agonist activity (Whistler et al.,
term use of opiates causes physical dependence in 1999), indicating that MOR endocytosis is an indepen-
some patients, a requirement for continued administra- dent functional property. Since agonist activity and re-
tion of increasing doses of drug to prevent the develop- ceptor endocytosis have opposing effects on receptor-
ment of symptoms of opiate withdrawal. Despite consid- mediated signaling, the net amount of signal transmitted
erable progress, the molecular and cellular mechanisms to the cell is a function of both processes, a relationship
mediating the development of tolerance and depen- we term RAVE for relative activity versus endocytosis
dence to morphine remain controversial (Nestler, 1996, (Whistler et al., 1999). Thus, morphine would have a
2001; Williams et al., 2001). particularly high RAVE value as a consequence of its
Studies using knockout mice confirm that opiate anal- inability to promote receptor desensitization and endo-
cytosis. Endorphins and opiate drugs that acutely signal
with similar efficacy, yet induce receptor desensitization4 Correspondence: shooz2@itsa.ucsf.edu
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Figure 1. MORs Oligomerize in HEK 293 Cells, and this Affects Receptor Trafficking
(a) Cells stably expressing both FLAG-MOR and a chimeric HA-D MOR were treated with morphine (MS), etorphine (ET), or left untreated (NT).
Cells were permeabilized and receptors were immunoprecipitated with anti-FLAG antibodies, resolved by SDS-PAGE, and transferred. Oligo-
mers were detected by immunoblotting with antibodies directed against the HA tag of the D MOR receptor (upper panel). As controls, an
aliquot of the immunoprecipitate was also immunoblotted with anti-FLAG antibodies (lower panel). Cells expressing only FLAG-MOR (upper
panel, left lane) or no receptor (293, lower panel, left lane) were used as controls for antibody specificity.
(b and c) Cells stably expressing FLAG-MOR, HA-D MOR, or both receptors were fed antibody to the extracellular epitope tag of the receptor
and examined for receptor distribution following morphine treatment (5 M, 30 min). (b) MORs were distributed primarily on the cell surface
in cells expressing only MOR, whereas D MORs were redistributed to endocytic vesicles. (c) In cells coexpressing both receptors, not only
D MORs but also MORs were redistributed to endocytic vesicles, with a significant number of vesicles showing colocalization of both receptors
(yellow in right panel).
and endocytosis, would have lower RAVE values than they signal through the receptor for aberrantly long peri-
ods of time. It follows that if prolonged signaling atmorphine.
These observations have led us to propose that drugs MOR contributes to the development of tolerance and
withdrawal, then molecular events that reduce this pro-with high RAVE values, such as morphine, have an en-
hanced propensity to produce the adverse effects asso- longed signaling, such as desensitization and endocyto-
sis, would reduce the development of these side effects.ciated with prolonged drug exposure, precisely because
MOR Endocytosis Reduces Morphine Tolerance
273
Figure 2. D MOR Affects the Trafficking of
MOR in Hippocampal Neurons
Three-week-old hippocampal cultures were
transfected with FLAG-MOR, HA-D MOR, or
both receptors. Neurons were then examined
for receptor distribution following antibody
feeding and morphine treatment (5 M, 30
min). MORs in neurons expressing only this
receptor were distributed primarily on the cell
surface (upper left panel). D MORs were rap-
idly redistributed to endocytic vesicles upon
morphine activation (upper right panel). In
neurons that coexpressed MOR and D MOR,
both receptors were redistributed to endo-
cytic vesicles following activation by mor-
phine (lower panels: left, MOR; right, D MOR).
Consistent with this hypothesis, we have recently dem- Results
onstrated that enhancing morphine-induced endocyto-
sis by receptor mutation reduces the development of The MOR Forms Oligomers
with a D MOR Receptortolerance and withdrawal in a cell culture model as as-
First, we examined whether the wild-type MOR couldsessed by superactivation of the cAMP pathway (Finn
form heterodimers with a previously described mutantand Whistler, 2001). In addition, methadone, an agonist
MOR, D MOR, that has altered trafficking propertiesthat promotes endocytosis of the wild-type MOR, pro-
(Finn and Whistler, 2001; Whistler et al., 1999). The D MORduces less superactivation in our cell culture model,
receptor is a chimera in which the cytoplasmic tail ofconsistent with its reduced RAVE value. Receptor muta-
the MOR has been replaced by the corresponding resi-tions that block methadone-induced endocytosis, thus
dues of the delta opioid receptor. This confers upon thisincreasing the RAVE value of methadone, exacerbate
receptor a gain-of-function phenotype whereby mor-cellular withdrawal. Furthermore, previous studies in an-
phine can promote receptor phosphorylation, arrestinimal models have provided evidence that agonists that
recruitment, and endocytosis (Whistler et al., 1999). Hu-promote receptor endocytosis have reduced propensity
man embryonic kidney (HEK) 293 cell lines stably trans-for causing tolerance and dependence when they are
fected with both a FLAG-tagged MOR and an HA-taggedadministered at equi-analgesic doses (Duttaroy and Yo-
D MOR were generated. Cells were treated with mor-burn, 1995; Rezvani et al., 1983; Stevens and Yaksh, 1989).
phine (MS) or etorphine (ET) or left untreated (NT), andRecently, several groups have reported dimerization
the FLAG-tagged MORs were immunoprecipitated. Im-of GPCRs (Angers et al., 2000; Lee et al., 2000) including
munoprecipitates were separated by SDS-PAGE andopioid receptors (Jordan and Devi, 1999). In fact, hetero-
immunoblotted with anti-FLAG antibodies as a control,dimerization of opioid receptors has been shown to alter
or anti-HA antibodies to detect D MOR and hence di-opiate ligand properties (Jordan and Devi, 1999) and
mers/oligomers. The D MOR receptor efficiently coim-affect receptor trafficking (Jordan et al., 2001). Here we
munoprecipitated with the MOR (Figure 1a). Dimeriza-report that opioid receptors can oligomerize in our cell
tion did not appear to be ligand-dependent (Figure 1a).culture system and affect trafficking of the receptors.
We have used this observation to begin to explore what
role receptor oligomerization might play in ligand-medi- Receptor Oligomerization Alters
ated signaling from opioid receptors and whether recep- MOR Trafficking Properties
tor oligomerization can alter the RAVE value of particular We next assessed whether the heterodimerization of
receptor agonists. These studies have allowed us to MOR and D MOR could affect the trafficking of the re-
address the RAVE hypothesis both in cell culture sys- ceptors using immunocytochemical methods. The dou-
tems and in animal models of behavior, and have pro- ble stable cell lines above were fed antibodies to the
vided in vivo evidence that endocytosis of the MOR can N-terminal extracellular tags of the FLAG-MOR and
reduce the development of tolerance to morphine in a HA-D MOR. Cells were treated with morphine and fixed.
Cell lines expressing only one receptor, either FLAG-rat model of opiate tolerance.
Cell
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MOR or HA-D MOR, were treated analogously as con-
trols. Cells were then permeabilized and stained with
fluorescent conjugated secondary antibodies. In this
way, only receptors that were initially on the cell surface
were detected. As expected, cells expressing only MOR
failed to show significant receptor endocytosis when
treated with morphine, whereas the D MOR receptor
efficiently internalized (Figure 1b). In contrast, the MOR
in the cell line that coexpressed D MOR underwent sig-
nificant endocytosis in the presence of morphine, with
a substantial number of vesicles showing colocalization
of both receptors (Figure 1c). We called this phenome-
non “dragging” because it appeared that the D MORs
could drag the MORs into the cell in response to mor-
phine, presumably because these receptors were mak-
ing heterodimers (Figure 1a).
The D MOR Affects MOR Trafficking
in Cultured Neurons
To ensure that this phenomenon was not an artifact of
the HEK 293 cell model, we examined whether dragging
also occurred in cultured neurons. Hippocampal neuron
cultures were prepared from rat and were allowed to
mature for three weeks. Cultures were then transfected
with FLAG-MOR alone, HA-D MOR alone, or both recep- Figure 3. DAMGO Facilitated Morphine-Induced MOR Endocytosis
tors. Cultures were fed anti-FLAG and/or anti-HA antibod- HEK 293 cells expressing only wild-type MOR were analyzed for
receptor distribution following treatment with various agonists. Aies, then treated for 30 min with morphine. As previously
saturating concentration of DAMGO (5M, 30 min) promoted robustreported (Whistler et al., 1999), neurons expressing MOR
endocytosis of MOR (upper left panel), whereas morphine at thealone expressed receptor primarily on the plasma mem-
same dose had little effect on receptor distribution (upper rightbrane following morphine treatment (Figure 2, upper left
panel). A subsaturating dose of DAMGO (100 nM) caused reduced
panel). In contrast, cells expressing D MOR alone endocytosis compared to a saturating dose (lower left panel). How-
showed efficient redistribution of receptors to endocytic ever, this subsaturating dose of DAMGO (100 nM), when adminis-
tered concurrently with a saturating dose of morphine (5 M), facili-vesicles following activation by morphine (Figure 2, up-
tated robust endocytosis of the MOR (lower right panel).per right panel). Importantly, in neurons that expressed
both receptors, both the D MOR and the wild-type MOR
were redistributed to endocytic vesicles following acti-
receptor endocytosis (Figure 3, lower left), presumablyvation by morphine (Figure 2, lower panels). These re-
because of low receptor occupancy.sults demonstrate that the D MOR receptor can drag
We next asked whether these few DAMGO-occupiedthe MOR into neurons.
receptors could drag morphine-occupied receptors into
the cell. To accomplish this, we treated cells simultane-
ously with the nonsaturating dose of DAMGO (100 nM)DAMGO Facilitates Morphine-Induced
Endocytosis of MOR and a saturating dose of morphine (5 M). Assuming all
receptors are monomers, one would predict that theWe have also observed that wild-type MORs can homo-
dimerize with one another just as they heterodimerize saturating dose of morphine would act as an antagonist
for the submaximal endocytosis induced by the subsat-with D MOR (data not shown). Because of this observa-
tion, we designed an experiment to ask whether we urating dose of DAMGO. Remarkably, cells treated in
this way showed robust receptor endocytosis (Figure 3,could facilitate receptor dragging using the pharmacol-
ogy of different MOR agonists. DAMGO, a hydrolysis- lower right). We attribute this phenomenon to the ability
of a few DAMGO-activated receptors to drag severalresistant derivative of enkephalin, promotes robust en-
docytosis of the MOR (Keith et al., 1996) and has an morphine activated receptors into the cell.
These results suggest that the receptors are makingaffinity for the MOR similar to that of morphine (Raynor
et al., 1994). These observations allowed us to address oligomers rather than simple dimers and that a single
DAMGO-occupied receptor in an oligomeric complexwhether a DAMGO-occupied MOR could drag a mor-
phine-occupied MOR into the cell. HEK 293 cells ex- with other morphine-occupied receptors is sufficient to
recruit the endocytic machinery and facilitate oligomerpressing only wild-type MOR were treated with a satu-
rating dose of DAMGO (5 M) or a saturating dose of internalization. Alternatively, it suggests that the few
DAMGO-activated receptors in the cell are bringing amorphine (5 M). As expected, cells treated with
DAMGO showed robust endocytosis of receptor (Figure high local concentration of the endocytic machinery, in
particular arrestin, to the morphine-activated receptors.3, upper left), while cells treated with morphine showed
little endocytosis of receptor (Figure 3, upper right). We have demonstrated previously that overexpression
of arrestin can facilitate morphine-induced endocytosisWhen we treated the same cells with a nonsaturating
dose of DAMGO (100 nM), there was significantly less of wild-type MOR (Whistler and von Zastrow, 1998). To
MOR Endocytosis Reduces Morphine Tolerance
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Figure 4. The B2AR Did Not Drag Morphine-Activated MORs into Cells
Cells stably expressing FLAG-MOR and HA-B2AR were fed antibody to the extracellular epitope tags of the receptors and examined for
receptor distribution following various agonist treatments (all 5 M, 30 min).
(a) MOR and B2AR were distributed primarily on the cell surface in the absence of agonist.
(b) DAMGO facilitated MOR endocytosis but not B2AR endocytosis.
(c) Isoproterenol facilitated B2AR endocytosis but not MOR endocytosis.
(d) In the presence of both agonists, both receptors were efficiently internalized and showed significant colocalization (yellow in merge panel).
(e) Isoproterenol-activated B2AR receptors failed to drag morphine-activated MORs into the cell.
Cell
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differentiate between these possibilities, we examined
whether an unrelated GPCR, the-2 adrenergic receptor
(B2AR), when activated, could facilitate the heterolo-
gous endocytosis of the morphine-activated MOR.
HEK 293 cells were generated that stably expressed
both the FLAG-tagged MOR and an HA-tagged B2AR.
Cells were incubated with antibodies to both epitope
tags to label cell surface receptors, treated with various
agonists or agonist combinations, then stained for both
receptors. Both receptors were expressed primarily on
the cell surface in the absence of agonist (Figure 4a).
As expected, DAMGO promoted endocytosis of the
MOR but not B2AR (Figure 4b), while the B2AR receptor
agonist isoproterenol (iso) promoted B2AR receptor but
not MOR endocytosis (Figure 4c). In the presence of
both agonists, both receptors were efficiently internal-
Figure 5. DAMGO Reduced Morphine-Induced cAMP Superactivation
ized (Figure 4d). However, isoproterenol-activated
Cells stably expressing MOR and a CRE-luciferase reporter geneB2ARs were not able to drag morphine-activated MORs
were treated chronically (14 hr) with morphine, DAMGO, or both
into the cell (Figure 4e). These results suggest that heter- drugs, and superactivation of the cAMP pathway was assessed
ologous activation of the B2AR receptor and its conse- relative to untreated cells. Morphine (1 M) caused pronounced
superactivation (gray bars) (Finn and Whistler, 2001). DAMGO alsoquent membrane recruitment of arrestin (data not
caused superactivation in a dose-dependent manner. A dose ofshown) is insufficient to promote the endocytosis of
DAMGO that caused little superactivation (10 nM) when adminis-nearby MORs. Hence, it is likely that receptors must be
tered concurrently with the superactivation-inducing dose of mor-in an oligomeric complex in order for dragging to be
phine (1 M) reduced the morphine-induced superactivation (red
efficient. bar). P  0.01, two-way ANOVA, Tukey’s post test.
The precise mechanism whereby a small number of
DAMGO-occupied receptors facilitate endocytosis of the
morphine-activated receptors remains an intriguing ques- ducing the RAVE value of morphine and reducing the
tion, and one that we are actively pursuing. Nevertheless, compensatory adaptive cellular changes that lead to
knowing the mechanism by which this dragging is accom- upregulation of the cAMP pathway, at least in a cell
plished was not necessary for us to assess the functional culture model. Importantly, these observations allowed
consequences of “dragging by pharmacology.” us to design experiments to examine the role of receptor
endocytosis in the development of tolerance in an intact
animal.DAMGO Reduces Morphine-Induced
cAMP Superactivation
Chronic morphine treatment of animals, as well as cells DAMGO Facilitates Morphine-Induced
Endocytosis in Rat Spinal Cord Neuronsin culture, produces a compensatory upregulation of the
cAMP pathway (Sharma et al., 1975; Bonci and Williams, To begin these studies, we first assessed whether we
could facilitate morphine-induced endocytosis of the1997; Avidor-Reiss et al., 1996), an effect that has been
studied as a cellular hallmark of opiate withdrawal that MOR using a low dose of DAMGO in vivo. Rats were
implanted with an intrathecal catheter through whichwe have also demonstrated contributes directly to a
form of cellular tolerance (Finn and Whistler, 2001). Pre- either an acute injection of agonist could be given or
chronic drug could be administered by an osmotic miniviously we have demonstrated that receptor endocyto-
sis can reduce this compensatory upregulation (Finn pump. We first examined the effects of a single acute
injection of morphine and DAMGO on analgesia andand Whistler, 2001). Hence, we predicted that receptor
dragging could reduce superactivation in our cell culture endocytosis. Consistent with previous studies (Advokat,
1993; Malmberg and Yaksh, 1992; Trafton et al., 2000),model. We assessed the functional consequences of
dragging by pharmacology in a previously described cell an acute high dose of both DAMGO (0.3 nmoles) and
morphine (30 nmoles) produced profound analgesialine that expresses MOR and a CRE-luciferase reporter
gene (Finn and Whistler, 2001). As expected, morphine (Figure 6a). Following the behavioral testing, these ani-
mals were sacrificed and the distribution of MORs wasinduced substantial superactivation (Figure 5, gray bar).
DAMGO also induced superactivation in this cell line in examined using immunohistochemical staining. Neu-
rons from the lamina II of the spinal cord dorsal horna dose-dependent manner (Figure 4, black bars), despite
its ability to promote receptor endocytosis. We attribute were examined because they play an important role in
pain transmission (Yaksh, 1999). MOR was detected inthis to DAMGO’s enhanced potency (and hence greater
numerator value in its RAVE) compared to that of mor- numerous endosomes throughout the cell body of the
lamina II neurons of rats treated with 0.3 nmoles DAMGOphine (Avidor-Reiss et al., 1996). Remarkably, a low dose
of DAMGO (10 nM), which alone produced little superac- (Figure 6b, upper left panel), indicative of pronounced
receptor endocytosis. In contrast, the MORs in laminativation, substantially reduced superactivation when it
was administered simultaneously with a superactiva- II neurons of the rats treated with 30 nmoles of morphine,
which showed equivalent analgesia in the behavioraltion-inducing dose of morphine (1 M) (red bar).
Taken together, these data demonstrate that a sec- assay (Figure 6a), were primarily on the cell membrane
(Figure 6b, upper right panel).ond, endocytosis-promoting agonist can facilitate mor-
phine-induced receptor endocytosis, consequently re- We next assessed whether we could facilitate mor-
MOR Endocytosis Reduces Morphine Tolerance
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Figure 6. DAMGO Facilitated Morphine-In-
duced MOR Endocytosis in Rat Spinal Cord
Rats (4–6 per group) were implanted with an
IT catheter through which acute doses of
drug were administered.
(a) Analgesia. Tail flick latency was tested be-
fore and 30 min after drug administration. 0.3
nmoles of DAMGO or 30 nmoles of morphine
produced significant analgesia (*** p  0.001),
whereas 0.01 nmoles of DAMGO had no anal-
gesic effect (p 0.05) as shown by Student’s
t test.
(b) Endocytosis. Immediately following the
behavioral test, rats were perfused and MOR
distribution was assessed by immunohisto-
chemical staining of MORs in the lamina II
neurons of the spinal cord proximal to the
catheter. MORs were redistributed to endo-
cytic compartments following treatment with
0.3 nmoles of DAMGO. Little endocytosis was
observed following treatment with the equi-
analgesic dose of morphine (30 nmoles), or
with the subanalgesic dose of DAMGO (0.01
nmoles). However, MORs in rats treated si-
multaneously with 0.01 nmoles of DAMGO
and 30 nmoles of morphine were redistrib-
uted to endocytic vesicles. Quantification of
vesicles is listed below each image and was
achieved by encoding the slides and having
a second party count vesicles from a center
section of a Z stack for at least 8 cells per
condition from 2 rats per condition.
phine-induced endocytosis of MOR using DAMGO in examined the time course of intrathecal morphine toler-
ance. As above, rats were implanted with an intrathecalvivo. A very low dose of DAMGO was chosen to avoid
catheter through which chronic morphine at severalconfusion due to DAMGO-induced endocytosis. Consis-
doses was administered by mini pump. As shown intent with previous reports (Trafton et al., 2000), DAMGO,
Figure 7a, three different doses of morphine producedat a dose of 0.01 nmoles, produced neither significant
a significant antinociceptive effect for the first few days.antinociception in the tail-flick assay (Figure 6a) nor de-
However, antinociception was gradually reduced duringtectable MOR endocytosis in lamina II neurons (Figure
continuous exposure to morphine and was eventually6b, lower left panel). However, this low dose of DAMGO,
lost completely over 7 days, indicating that the rats hadwhen administrated concurrently with 30 nmoles of mor-
developed tolerance to morphine. To examine whetherphine, elicited a remarkable endocytosis in the spinal
the interaction between DAMGO and morphine, whichcord neurons (Figure 6b, lower right panel). These results
stimulated endocytosis of MOR acutely (see Figure 6b),clearly demonstrate that DAMGO and morphine differ-
could reduce the development of tolerance to chronicentially regulate MOR trafficking in the spinal cord and
morphine, we designed the following experiment. Ratsthat DAMGO can facilitate morphine-induced endocyto-
were implanted with a Y-shaped intrathecal catheter.sis in vivo, thereby altering the RAVE value of morphine.
One arm of the Y was connected to a mini pump through
which chronic morphine or saline was administered. Ei-
DAMGO Reduces Morphine Tolerance ther saline or a subanalgesic, subendocytic dose of
Using these observations, we designed a set of experi- DAMGO (0.01 nmoles; see Figures 6a and 6b) was ad-
ments to examine whether alteration of the RAVE value ministered twice daily through the other arm of the cath-
of morphine by DAMGO-mediated dragging would af- eter. Twice daily injection of 0.01 nmoles of DAMGO
produced no analgesia in the rats receiving saline fromfect the development of morphine tolerance. We first
Cell
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Figure 7. DAMGO Inhibited the Development
of Morphine Tolerance
(a) Rats were implanted with an IT catheter
and a time course of morphine tolerance de-
velopment was assessed with daily tail flick
latency testing before pump implantation (day
0) and for 7 consecutive days. Morphine was
chronically infused at 2, 6, or 18 nmoles/hr.
Morphine induced tolerance at all three doses.
(b) Rats were implanted with a Y-shaped IT
catheter. One arm of the catheter was
attached to a mini pump that was prefilled
with morphine and implanted subcutane-
ously. The other arm of the catheter was used
for daily injection of DAMGO or saline. 0.01
nmoles of DAMGO/15 l or the same volume
of saline were injected twice per day. Analge-
sia was assessed by tail flick latency test
once per day 30 min following the second
injection. The results were analyzed by two-
way ANOVA followed by Bonferroni post-test
(* p  0.05, ** p  0.01, *** p  0.001 versus
saline; $ p  0.05, $$ p  0.01 significantly
different from MS 6 nmole plus saline group.
N  4–6 per group, mean  SEM are shown).
There was no significant difference between
the MS 6 nmole plus DG 0.01 nmole group
and the MS 6 nmole plus saline group for the
first 3 days (p  0.05).
(c) Immunohistochemical staining of MORs in
the lamina II neurons of the spinal cord from
the rats in (b). MORs were primarily localized
to the plasma membrane of neurons of rats
treated with saline, morphine, or the low dose
of DAMGO. However, pronounced MOR endo-
cytosis was observed following coadministra-
tion of morphine with the low dose of DAMGO.
Quantification was achieved by encoding the
slides and having a second party count vesicles
from a center section of a Z stack for at least
8 cells from 2 rats per condition.
their mini pumps (Figure 7b, closed circles), consistent tent with the results obtained with this dose of DAMGO
acutely. The MORs in the spinal cord neurons of thewith the inability of this dose of DAMGO to produce
antinociception acutely (Figure 6a). Rats receiving mor- rats given chronic morphine were also predominantly
on the cell surface (Figure 7c, lower left panel), consis-phine chronically through their mini pumps and twice
daily injections of saline through the catheter showed tent with the results obtained with acute morphine in
spinal cord neurons of this study (see Figure 6b, upperpronounced antinociception early in the experiment but
developed tolerance to the effects of morphine within right panel) and other regions in previous studies (Keith
et al., 1998; Sternini et al., 1996). In contrast, the MORs4 days (Figure 7b, open squares). Rats receiving the
same dose of morphine through their minipumps and in the spinal cord neurons of the rats with a morphine
mini pump who received twice daily injection of 0.01also receiving twice daily injection of 0.01 nmoles of
DAMGO through their catheters showed antinociception nmoles DAMGO were distributed not only on the plasma
membrane but also within intracellular compartments,on day 1 comparable to that in the rats receiving saline
injections. However, remarkably, these rats did not de- suggesting that MORs in these rats were undergoing
endocytosis in response to a low dose of DAMGO invelop tolerance to morphine during the seven days of
this experiment (Figure 7b, closed squares). combination with chronic morphine. Taken together,
these results imply that a subanalgesic dose of a MORWe hypothesized that the failure of the rats receiving
both morphine and DAMGO to develop tolerance was agonist that promotes receptor endocytosis can facili-
tate the endocytosis of morphine-activated receptors ina reflection of the ability of a low dose of DAMGO to
alter the RAVE value of morphine by stimulating receptor the cell, thereby decreasing the RAVE value of morphine
and reducing the development of tolerance.endocytosis. To examine this possibility, we examined
the distribution of the MORs in the spinal cord of the
rats from the behavioral experiment. The distribution of Discussion
MORs in spinal cord neurons of the rats receiving twice
daily injection of 0.01 nmoles DAMGO and saline in the Here we show that a small, subanalgesic dose of
DAMGO, an agonist that promotes endocytosis of themini pump was indistinguishable from animals given
only saline (Figure 7c, compare top two panels), consis- MOR, facilitates morphine-induced endocytosis in trans
MOR Endocytosis Reduces Morphine Tolerance
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and thereby lowers the RAVE value of morphine and in various brain regions following chronic morphine treat-
reduces the development of tolerance. We propose that ment, often without a concomitant loss in receptor num-
oligomerization of the MOR influences the endocytic ber (Christie et al., 1987; Connor et al., 1999; Selley et al.,
properties of the receptor, and as a consequence of this 1997; Sim et al., 1996). Tolerance mediated by receptor
altered endocytosis, the development of tolerance to downregulation would lead to reduced receptor-mediated
morphine is reduced. Although we can not rule out the signaling because of a loss of surface receptors. Several
possibility that other mechanisms associated with the groups have reported that in some brain regions there is,
interaction of DAMGO and morphine could be affecting in fact, a loss of receptors following prolonged morphine
the development of tolerance to morphine, we favor the treatment (Abdelhamid and Takemori, 1991; Bernstein and
hypothesis that the rats treated with both drugs become Welch, 1998; Tao et al., 1998). However, in other regions,
less tolerant to the analgesic effects of morphine as a receptor number remains unchanged (De Vries et al.,
consequence of the decreased RAVE value of morphine. 1993; Simantov et al., 1984; Werling et al., 1989) or is
These results are consistent with our previous studies even upregulated in tolerant animals (Brady et al., 1989;
in cell culture that have demonstrated that increases in Gouarderes et al., 1990; Rothman et al., 1991; Tejwani
endocytosis reduce tolerance and withdrawal. However, et al., 1998). It is likely that all these mechanisms, and
these data provide in vivo evidence that suggests that potentially others as well, contribute to opiate tolerance.
alterations in the trafficking properties of the MOR in Furthermore, although cellular mechanisms, including re-
response to morphine can affect the development of ceptor number, desensitization, and homeostasis can
tolerance in an animal model of behavior. contribute to tolerance, additional complex mechanisms
It is likely that tolerance to opiate drugs, as well as involving alterations in neuronal circuitry are likely involved
other compounds that target GPCRs, is mediated by a in the development of associative tolerance (Mitchell et
complex set of mechanisms. We have previously shown al., 2000).
that tolerance to morphine in a cell culture model can The observation that -arrestin 2 knockout mice show
occur by at least two distinct mechanisms depending reduced analgesic tolerance (Bohn et al., 2000) suggests
on the endocytic and postendocytic properties of the that, in certain cell types, receptor desensitization may
receptor in response to morphine (Finn and Whistler, contribute directly to morphine tolerance, perhaps by
2001). Furthermore, Yoburn and colleagues have dem- serving as a first step toward receptor downregulation,
onstrated that opiate tolerance can occur by receptor although receptor number was not assessed in these
density-dependent and -independent mechanisms de- animals. These data are consistent with the prevailing
pending on whether or not the agonist used promotes hypothesis that receptor desensitization contributes di-
endocytosis (Stafford et al., 2001). rectly to tolerance. However, it is important to note that
Tolerance to morphine can occur as a result of super- the endocytic trafficking of several classes of GPCR are
activation of the adenylyl cyclase signaling pathway likely also affected by the loss of -arrestin in these
(Sharma et al., 1975), which masks morphine’s effect by animals, many of which may also be involved in pain
altering the homeostatic baseline of the MOR express- transmission. Furthermore, the -arrestin 2 knockout
ing cells. Several groups have reported superactivation mice still demonstrate withdrawal from morphine, as
of the cAMP signaling pathway in response to chronic assessed biochemically with cAMP superactivation.
morphine treatment in brain regions implicated in addic- Hence, cellular tolerance is still occurring in these ani-
tion, including the locus coeruleus (Nestler, 1996), ven- mals, even though behavioral tolerance is reduced.
tral tegmental area (Bonci and Williams, 1997), nucleus Clearly, the emerging picture of regional differences in
accumbens (Chieng and Williams, 1998; Terwilliger et the extent of chronic morphine-induced MOR desensiti-
al., 1991), amygdala (Terwilliger et al., 1991), and dorsal zation (Sim et al., 1996; Sim-Selley et al., 2000), as well
raphe (Jolas et al., 2000). Cellular changes occurring as regionally distributed splice variants differing in their
during cAMP superactivation include increased expres- cytoplasmic tails (Abbadie et al., 2000), promises to im-
sion of certain adenylyl cyclases, PKA, and CREB (re- part considerable complexity to the biochemical charac-
viewed in Nestler, 2001; Williams et al., 2001). These terization of the processes of desensitization and super-
adaptive cellular changes compensate for continued in-
activation in different brain regions.
hibition of adenylyl cyclase, and are functionally analo-
Nevertheless, here we have demonstrated that in-gous since they serve to increase the amount of signal-
creased MOR endocytosis in response to morphine caning through the cAMP pathway and thus subvert the
reduce the development of tolerance in an animal model.effect of morphine. This cellular tolerance is clearly re-
These results have important implications for the treat-vealed upon removal of drug, whereby the superactiva-
ment of chronic pain. First, they suggest that agoniststion manifests itself as withdrawal. Superactivation fol-
that promote endocytosis of the MOR might providelowing drug withdrawal demonstrates that the MORs
analgesics with reduced liability for tolerance. This is inin these cells are still coupled to second messenger
contrast to the prevailing hypothesis that desensitiza-cascades when drug is present, and hence this form of
tion and endocytosis of the MOR contributes directlytolerance would be receptor density-independent. This
to tolerance by decreasing the number of functionalcellular tolerance is alleviated by receptor endocytosis
receptors. It is important to note that agonists that pro-(Finn and Whistler, 2001).
mote desensitization of receptors are routinely dis-On the other hand, tolerance to morphine could also
carded in drug discovery programs precisely becauseoccur as a result of receptor desensitization or receptor
of this prevailing view. However, even without the devel-downregulation. Tolerance mediated solely by receptor
opment of new opiate analgesics, the results here sug-desensitization would lead to reduced receptor-mediated
gest that the development of tolerance to morphine cansignaling without a loss of surface receptors. Several
groups have reported reduced MOR-mediated signaling be delayed by the coadministration of drugs that promote
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approved by the Animal Care and Use Committee at Gallo Centerendocytosis. In short, our results suggest that two drugs
of the University of California, San Francisco.actually produce less tolerance than morphine alone.
Preparation and Implantation of Intrathecal (IT) Catheters
Experimental Procedures
Catheter implantation was performed according to methods of
Yaksh with minor modifications (Yaksh and Rudy, 1976; Yaksh and
Cell Culture and Immunocytochemistry
Stevens, 1986). Two types of catheters were prepared depending
Human Embryonic Kidney (HEK) 293 cells (American Type Culture
on the regimen for test drug delivery. For the morphine alone groups
Collection) were grown in DMEM (Gibco BRL) supplemented with
(and the saline only controls), a 3 cm length of polyethylene tubing,
10% Fetal Bovine Serum (Hyclone). Mu opioid receptor and CRE-
PE-60, was connected to an 8 cm length of PE-10 tubing by heating.
Luciferase (Promega) constructs were stably transfected using cal-
For the chronic morphine plus DAMGO/saline groups, a Y-shape
cium phosphate coprecipitation, with single colonies chosen and
catheter was prepared. For catheter implantation, rats were anes-
propagated in the presence of selection-containing media. For im-
thetized with isoflurane and placed on a stereotaxic device with the
munocytochemistry, cells were grown on poly-lysine coated cov-
head flexed forward. The PE-10 catheter was inserted into the spinal
erslips and incubated with 3.5 g/ml M1 anti-FLAG and/or 3.5 g/
subarachnoid space through an incision in the atlanto-occipital
ml HA-11 antibody (Covance) for 30 min. Cells were then treated
membrane and advanced caudally extending to the lumbar enlarge-
with agonist as specified, fixed in 4% formaldehyde in PBS, perme-
ment of the spinal cord. After implantation of IT catheters, rats were
abilized in 0.1% Triton X-100 in Blotto, and stained. Cells stained
returned to their home cages and allowed 7 days to recover from
for only one receptor type were stained with Texas red-conjugated
surgery. Those rats with normal motor function were implanted with
Donkey anti-Mouse antibody (Jackson Immunoresearch). Cells that
a subcutaneous mini-osmotic pump (Model 2001, DURECT Corp.,
were stained for both FLAG and HA tagged receptors simultaneously
Cupertino, CA) that had been prefilled with morphine or saline on
were first incubated with rabbit anti-IgG2b antibodies (Zymed) fol- the dorsal part of neck under light isoflurane anesthesia.
lowed by staining with Texas red Donkey anti Rabbit antibody (Jack-
son Immunoresearch) and FITC-conjugated Goat anti Mouse IgG1
Drug Treatmentsantibody (Boehringer). Images were acquired using a custom-con-
DAMGO and morphine sulfate were purchased from Sigma (St.figured inverted microscope (Prairie Systems, Madison, WI) with a
Louis, MO) and dissolved in 0.9% physiological saline. The testZeiss 63 oil objective, or a Zeiss confocal with a 60 oil objective.
drug was delivered via either single injection or chronic infusion.
Morphine or saline was infused via mini-osmotic pump at a constant
Immunoprecipitation rate of 1 l/hr. DAMGO or saline was injected through one arm of
Cells were grown to 80% confluency in 10 cm dishes and treated the Y-shape catheter at 15 l volume.
with 5 M agonist for 30 min or left untreated. Cells were washed
2 in PBS and lysed in NDM lysis buffer (10 mM HEPES [pH 7.5], 150
Antinociception Test
mM NaCl, 2 mM MgCl, 1 mM CaCl, 0.5% n-dodecyl--D-maltoside).
Rats were tested for antinociception using the radiant heat tail-flick
Lysate was cleared by centrifugation at 10,000 rpm for 10 min at
procedure. The light intensity was adjusted to achieve base-line
4C, and cleared lysate was immunoprecipitated with 40 l M2-
latencies of 1.5 to 2 s; a maximum latency of 6 s was set as the
conjugated sepharose (Covance) overnight at 4C. Immunoprecipi-
cutoff time to minimize damage to the tail. For the morphine alone
tates were extensively washed with NDM buffer followed by 2
group and the saline controls, the animals were tested by tail-flick
washes with 10 mM Tris (pH 7.5). Receptors were deglycosylated
once a day for 7 days following implantation of the mini-osmotic
with PNGase (NEB) in 10 mM Tris (pH 7.5) for 2 hr at 37C, denatured
pump. For the morphine plus DAMGO and morphine plus saline
with SDS sample buffer, and resolved by SDS-PAGE. Blots were
groups, following mini pump implantation, rats were administrated
blocked in Blotto, incubated with a biotinylated M2 anti FLAG anti-
DAMGO or saline via the other arm of the Y-shape catheter twice
body (1:250, Covance) for 2 hr, and developed with streptavidin
a day for 7 days at 9:00 AM and 4:30 PM. Antinociception was tested
overlay using ABC reagents (Vector laboratories) and ECL reagents
by tail-flick 30 min after the afternoon administration. The behavioral
(Amersham) as a control, or incubated with HA-11 antibody (1:1000
data of antinociception were compared and statistically analyzed
Covance) for 2 hr and HRP-conjugated Goat anti mouse (1:3000,
by two-way analysis of variance followed by Bonferroni post-test,
Jackson Immunoresearch) for 1 hr and developed with ECL reagents
where P  0.05 was considered significant.
to detect oligomers.
Immunohistochemistry
CRE-Luciferase Reporter Expression Assays The rats were anesthetized with intramuscular ketamine hydrochlo-
Cells were grown to confluency in 24 well plates. For acute experi- ride (80 mg/kg) and xylazine hydrochloride (12 mg/kg) and perfused
ments, cells were given drug for 4 hr and the fold inhibition of forskolin- with 4% paraformaldehyde in 0.1 M phosphate buffer immediately
stimulated luciferase activity measured. For chronic treatment experi- following the tail-flick test at day 7 following pump implantation.
ments, cells were given drug for 14 hr, rinsed 3 times in drug-free The segment of spinal cord proximal to the tip of the catheter was
media to initiate a withdrawal phase, then given 2 M forskolin for the dissected out, post-fixed overnight in the same fixative, and then
4 hr withdrawal phase, and luciferase activity measured. 14 hr was transferred to a 30% sucrose buffer solution. Sagittal sections (30
chosen after an initial time course of morphine-induced superactiva- m) were cut on a freezing microtome, preincubated in PBT solution
tion in MOR-expressing HEK293 cells demonstrated that superacti- (0.1 M phosphate buffer 	 0.2% BSA and 0.2% Triton X-100) for 30
vation at this time point was highly reproducible. For all treatment min, blocked in 5% normal goat serum in PBT solution for another
conditions, cells were rinsed once in PBS immediately prior to lucif- 30 min, and then incubated in a rabbit anti-MOR antibody (DiaSorin,
erase measurement. 100 l Cell Culture Lysis Reagent (Promega) Stillwater, MN) at a 1:5000 dilution and mouse anti-NeuN antibody
was added to each well, a 20 l cell lysate aliquot was transferred to identify the neurons in the section (Mullen et al., 1992) (Chemicon
to an opaque 96 well plate, 100 l substrate added per well using International, Temecula, CA) at 1:300 overnight at 4C. Sections
a Lucy 2 luminometer (Anthos), and light measurements collected. were extensively washed with PBT and incubated in Cy-3-conju-
Data were exported to Microsoft Excel for compilation, and Graph- gated goat anti-rabbit antibody (Jackson Immunoresearch, West
Pad Prism 3.0 for graphical display, nonlinear regression curve fit- Grove, PA) and FITC-conjugated goat anti-mouse antibody (Jackson
ting, and subsequent statistical analyses. Immunoresearch) both at a 1:600 dilution for 2 hr at room tempera-
ture. The sections were then washed and mounted on slides. MOR
distribution was examined with a Zeiss confocal microscope usingAnimals
Male Sprague-Dawley rats (250–300 g, Simonsen Laboratories, Inc., a 60 oil immersion objective. For quantification, slides from at
least two different rats for each condition were stained by one re-Gilroy, CA) were housed individually in temperature-controlled
rooms with a 12 hr light/dark cycle. Food and water were available searcher and encoded, and vesicles were counted blind by a second
individual from the middle section of at least 8 cells per condition.ad libitum. All procedures used in this study were in agreement with
the NIH Guide for the Care and Use of Laboratory Animals and were Following compilation of vesicle counts, the code was broken.
MOR Endocytosis Reduces Morphine Tolerance
281
Acknowledgments Ferguson, S.S. (2001). Evolving concepts in G protein-coupled re-
ceptor endocytosis: the role in receptor desensitization and signal-
ing. Pharmacol. Rev. 53, 1–24.We are grateful to Jodie Trafton and Wes Chang for assistance with
immunohistochemical staining and Ling Wang for instruction on Finn, A.K., and Whistler, J.L. (2001). Endocytosis of the mu opioid
hippocampal neuron culture. We thank Craig Stevens, Tony Yaksh, receptor reduces tolerance and a cellular hallmark of opiate with-
and Byron Yoburn for instruction on IT catheter implantation, and drawal. Neuron 32, 829–839.
Howard Fields, Andrew Finn, Patricia Janak, and Dorit Ron for criti-
Gouarderes, C., Jhamandas, K., Zajac, J.M., Beaudet, A., Cros, J.,
cal reading of the manuscript. This research was supported by funds
and Quirion, R. (1990). Modulation of mu opioid binding sites in rat
provided by NIH/NIDA to M.v.Z. and J.L.W. and by the State of
spinal cord by chronic intrathecal infusion of morphine and nalox-
California for medical research on alcohol and substance abuse
one: a quantitative autoradiography approach. Prog. Clin. Biol. Res.
through the University of California San Francisco to J.L.W.
328, 175–178.
Hughes, J., and Kosterlitz, H.W. (1983). Opioid Peptides: introduc-Received November 19, 2001; revised December 20, 2001.
tion. Br. Med. Bull. 39, 1–3.
Jolas, T., Nestler, E.J., and Aghajanian, G.K. (2000). Chronic mor-References
phine increases GABA tone on serotonergic neurons of the dorsal
raphe nucleus: association with an up-regulation of the cyclic AMPAbbadie, C., Pan, Y.X., and Pasternak, G.W. (2000). Differential distri-
pathway. Neuroscience 95, 433–443.bution in rat brain of mu opioid receptor carboxy terminal splice
variants MOR-1C-like and MOR-1-like immunoreactivity: evidence Jordan, B.A., and Devi, L.A. (1999). G-protein-coupled receptor het-
for region-specific processing. J. Comp. Neurol. 419, 244–256. erodimerization modulates receptor function. Nature 399, 697–700.
Abdelhamid, E.E., and Takemori, A.E. (1991). Characteristics of mu Jordan, B.A., Trapaidze, N., Gomes, I., Nivarthi, R., and Devi, L.A.
and delta opioid binding sites in striatal slices of morphine-tolerant (2001). Oligomerization of opioid receptors with beta 2-adrenergic
and -dependent mice. Eur. J. Pharmacol. 198, 157–163. receptors: a role in trafficking and mitogen-activated protein kinase
activation. Proc. Natl. Acad. Sci. USA 98, 343–348.Advokat, C. (1993). Intrathecal coadministration of serotonin and
morphine differentially modulates the tail-flick reflex of intact and Keith, D.E., Murray, S.R., Zaki, P.A., Chu, P.C., Lissin, D.V., Kang,
spinal rats. Pharmacol. Biochem. Behav. 45, 871–879. L., Evans, C.J., and von Zastrow, M. (1996). Morphine activates
opioid receptors without causing their rapid internalization. J. Biol.Angers, S., Salahpour, A., Joly, E., Hilairet, S., Chelsky, D., Dennis,
Chem. 271, 19021–19024.M., and Bouvier, M. (2000). Detection of beta 2-adrenergic receptor
dimerization in living cells using bioluminescence resonance energy Keith, D.E., Anton, B., Murray, S.R., Zaki, P.A., Chu, P.C., Lissin, D.V.,
transfer (BRET). Proc. Natl. Acad. Sci. USA 97, 3684–3689. Monteillet-Agius, G., Stewart, P.L., Evans, C.J., and von Zastrow,
M. (1998). mu-Opioid receptor internalization: opiate drugs haveArden, J.R., Segredo, V., Wang, Z., Lameh, J., and Sadee, W. (1995).
differential effects on a conserved endocytic mechanism in vitroPhosphorylation and agonist-specific intracellular trafficking of an
and in the mammalian brain. Mol. Pharmacol. 53, 377–384.epitope-tagged mu-opioid receptor expressed in HEK 293 cells.
J. Neurochem. 65, 1636–1645. Lee, S.P., Xie, Z., Varghese, G., Nguyen, T., O’Dowd, B.F., and
George, S.R. (2000). Oligomerization of dopamine and serotoninAvidor-Reiss, T., Nevo, I., Levy, R., Pfeuffer, T., and Vogel, Z. (1996).
receptors. Neuropsychopharmacology 23, S32–S40.Chronic opioid treatment induces adenylyl cyclase V superactiva-
tion. Involvement of Gbetagamma. J. Biol. Chem. 271, 21309–21315. Lefkowitz, R.J., Pitcher, J., Krueger, K., and Daaka, Y. (1998). Mecha-
nisms of beta-adrenergic receptor desensitization and resensitiza-Bernstein, M.A., and Welch, S.P. (1998). mu-Opioid receptor down-
tion. Adv. Pharmacol. 42, 416–420.regulation and cAMP-dependent protein kinase phosphorylation in
a mouse model of chronic morphine tolerance. Brain Res. Mol. Brain Malmberg, A.B., and Yaksh, T.L. (1992). Isobolographic and dose-
Res. 55, 237–242. response analyses of the interaction between intrathecal mu and
delta agonists: effects of naltrindole and its benzofuran analogBlake, A.D., Bot, G., Freeman, J.C., and Reisine, T. (1997). Differential
(NTB). J. Pharmacol. Exp. Ther. 263, 264–275.opioid agonist regulation of the mouse mu opioid receptor. J. Biol.
Chem. 272, 782–790. Matthes, H.W., Maldonado, R., Simonin, F., Valverde, O., Slowe, S.,
Kitchen, I., Befort, K., Dierich, A., Le Meur, M., Dolle, P., et al. (1996).Bohn, L.M., Gainetdinov, R.R., Lin, F.T., Lefkowitz, R.J., and Caron,
Loss of morphine-induced analgesia, reward effect and withdrawalM.G. (2000). Mu-opioid receptor desensitization by beta-arrestin-2
symptoms in mice lacking the mu-opioid-receptor gene. Nature 383,determines morphine tolerance but not dependence. Nature 408,
819–823.720–723.
Mitchell, J.M., Basbaum, A.I., and Fields, H.L. (2000). A locus andBonci, A., and Williams, J.T. (1997). Increased probability of GABA
mechanism of action for associative morphine tolerance. Nat. Neu-release during withdrawal from morphine. J. Neurosci. 17, 796–803.
rosci. 3, 47–53.Brady, L.S., Herkenham, M., Long, J.B., and Rothman, R.B. (1989).
Mullen, R.J., Buck, C.R., and Smith, A.M. (1992). NeuN, a neuronalChronic morphine increases mu-opiate receptor binding in rat brain:
specific nuclear protein in vertebrates. Development 116, 201–211.a quantitative autoradiographic study. Brain Res. 477, 382–386.
Nestler, E.J. (1996). Under siege: The brain on opiates. Neuron 16,Chieng, B., and Williams, J.T. (1998). Increased opioid inhibition of
897–900.GABA release in nucleus accumbens during morphine withdrawal.
J. Neurosci. 18, 7033–7039. Nestler, E.J. (2001). Molecular basis of long-term plasticity underly-
ing addiction. Nat. Rev. Neurosci. 2, 119–128.Christie, M.J., Williams, J.T., and North, R.A. (1987). Cellular mecha-
nisms of opioid tolerance: studies in single brain neurons. Mol. Raynor, K., Kong, H., Chen, Y., Yasuda, K., Yu, L., Bell, G.I., and
Pharmacol. 32, 633–638. Reisine, T. (1994). Pharmacological characterization of the cloned
kappa-, delta-, and mu-opioid receptors. Mol. Pharmacol. 45,Connor, M., Schuller, A., Pintar, J.E., and Christie, M.J. (1999). Mu-
330–334.opioid receptor modulation of calcium channel current in periaque-
ductal grey neurons from C57B16/J mice and mutant mice lacking Rezvani, A., Huidobro-Toro, J.P., Hu, J., and Way, E.L. (1983). A rapid
MOR-1. Br. J. Pharmacol. 126, 1553–1558. and simple method for the quantitative determination of tolerance
development to opiates in the guinea-pig ileum in vitro. J. Pharma-De Vries, T.J., Tjon Tien Ril, G.H., Van der Laan, J.W., Mulder, A.H.,
col. Exp. Ther. 225, 251–255.and Schoffelmeer, A.N. (1993). Chronic exposure to morphine and
naltrexone induces changes in catecholaminergic neurotransmis- Rothman, R.B., Long, J.B., Bykov, V., Xu, H., Jacobson, A.E., Rice,
sion in rat brain without altering mu-opioid receptor sensitivity. Life K.C., and Holaday, J.W. (1991). Upregulation of the opioid receptor
Sci. 52, 1685–1693. complex by the chronic administration of morphine: a biochemical
marker related to the development of tolerance and dependence.Duttaroy, A., and Yoburn, B.C. (1995). The effect of intrinsic efficacy
on opioid tolerance. Anesthesiology 82, 1226–1236. Peptides 12, 151–160.
Cell
282
Selley, D.E., Nestler, E.J., Breivogel, C.S., and Childers, S.R. (1997). Zhang, J., Ferguson, S.S., Barak, L.S., Bodduluri, S.R., Laporte,
S.A., Law, P.Y., and Caron, M.G. (1998). Role for G protein-coupledOpioid receptor-coupled G-proteins in rat locus coeruleus mem-
branes: decrease in activity after chronic morphine treatment. Brain receptor kinase in agonist-specific regulation of mu-opioid receptor
responsiveness. Proc. Natl. Acad. Sci. USA 95, 7157–7162.Res. 746, 10–18.
Sharma, S.K., Klee, W.A., and Nirenberg, M. (1975). Dual regulation
of adenylate cyclase accounts for narcotic dependence and toler-
ance. Proc. Natl. Acad. Sci. USA 72, 3092–3096.
Sim, L.J., Selley, D.E., Dworkin, S.I., and Childers, S.R. (1996). Effects
of chronic morphine administration on mu opioid receptor-stimu-
lated [35S]GTPgammaS autoradiography in rat brain. J. Neurosci.
16, 2684–2692.
Sim-Selley, L.J., Selley, D.E., Vogt, L.J., Childers, S.R., and Martin,
T.J. (2000). Chronic heroin self-administration desensitizes mu opi-
oid receptor-activated G-proteins in specific regions of rat brain. J.
Neurosci. 20, 4555–4562.
Simantov, R., Lotem, J., and Levy, R. (1984). Selectivity in the control
of opiate receptor density in the animal and in cultured fetal brain
cells. Neuropeptides 5, 197–200.
Stafford, K., Gomes, A.B., Shen, J., and Yoburn, B.C. (2001). mu-
Opioid receptor downregulation contributes to opioid tolerance in
vivo. Pharmacol. Biochem. Behav. 69, 233–237.
Sternini, C., Spann, M., Anton, B., Keith, D.J., Bunnett, N.W., von
Zastrow, M., Evans, C., and Brecha, N.C. (1996). Agonist-selective
endocytosis of mu opioid receptor by neurons in vivo. Proc. Natl.
Acad. Sci. USA 93, 9241–9246.
Stevens, C.W., and Yaksh, T.L. (1989). Potency of infused spinal
antinociceptive agents is inversely related to magnitude of tolerance
after continuous infusion. J. Pharmacol. Exp. Ther. 250, 1–8.
Tao, P.L., Han, K.F., Wang, S.D., Lue, W.M., Elde, R., Law, P.Y., and
Loh, H.H. (1998). Immunohistochemical evidence of down-regula-
tion of mu-opioid receptor after chronic PL-017 in rats. Eur. J. Phar-
macol. 344, 137–142.
Tejwani, G.A., Sheu, M.J., Sribanditmongkol, P., and Satyapriya, A.
(1998). Inhibition of morphine tolerance and dependence by diaze-
pam and its relation to micro-opioid receptors in the rat brain and
spinal cord. Brain Res. 797, 305–312.
Terwilliger, R.Z., Beitner-Johnson, D., Sevarino, K.A., Crain, S.M.,
and Nestler, E.J. (1991). A general role for adaptations in G-proteins
and the cyclic AMP system in mediating the chronic actions of
morphine and cocaine on neuronal function. Brain Res. 548,
100–110.
Trafton, J.A., Abbadie, C., Marek, K., and Basbaum, A.I. (2000).
Postsynaptic signaling via the mu-opioid receptor: responses of
dorsal horn neurons to exogenous opioids and noxious stimulation.
J. Neurosci. 20, 8578–8584.
Trapaidze, N., Gomes, I., Cvejic, S., Bansinath, M., and Devi, L.A.
(2000). Opioid receptor endocytosis and activation of MAP kinase
pathway. Brain Res. Mol. Brain Res. 76, 220–228.
Werling, L.L., McMahon, P.N., and Cox, B.M. (1989). Selective
changes in mu opioid receptor properties induced by chronic mor-
phine exposure. Proc. Natl. Acad. Sci. USA 86, 6393–6397.
Whistler, J.L., and von Zastrow, M. (1998). Morphine-activated opi-
oid receptors elude desensitization by beta-arrestin. Proc. Natl.
Acad. Sci. USA 95, 9914–9919.
Whistler, J.L., Chuang, H.-H., Chu, P., Jan, L.Y., and von Zastrow,
M. (1999). Functional dissociation of mu opioid receptor signaling
and endocytosis: implications for the biology of tolerance and addic-
tion. Neuron 23, 737–746.
Williams, J.T., Christie, M.J., and Manzoni, O. (2001). Cellular and
synaptic adaptations mediating opioid dependence. Physiol. Rev.
81, 299–343.
Yaksh, T.L. (1999). Spinal systems and pain processing: develop-
ment of novel analgesic drugs with mechanistically defined models.
Trends Pharmacol. Sci. 20, 329–337.
Yaksh, T.L., and Rudy, T.A. (1976). Chronic Catheterization of the
Spinal Subarachnoid Space. Physiol. Behav. 17, 1031–1036.
Yaksh, T.L., and Stevens, C.W. (1986). Simple catheter preparation
for permitting bolus intrathecal administration during chronic in-
trathecal infusion. Pharmacol. Biochem. Behav. 25, 483–485.
